COVID-19 mortality and obstructive airways disease
COVID-19 mortality and obstructive airways disease

COVID-19 mortality and obstructive airways disease

Patients admitted with COVID-19 who have comorbid asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO) have a significantly lower survival probability than patients without these comorbidities, according to research presented at the American Academy of Allergy. Annual Meeting for Asthma and Immunology (AAAAI) 2022, held in Phoenix, Arizona, February 25-28.


Keep reading

In an attempt to determine the effects of obstructive airways disease on COVID-19 outcomes, researchers in Korea conducted a study involving 5,625 patients admitted to COVID-19, which was divided into asthma, COPD, ACO and control groups. Patient data were analyzed to determine the likelihood of survival as well as factors affecting COVID-19 mortality, severity of disease, and oxygen demand.

The researchers found that mortality among patients in the asthma, COPD, and ACO groups was 2.3, 4.8, and 5.5 times higher, respectively, than among patients in the control group. The investigators further noted that patients with asthma, COLand ACO groups were more likely to require oxygen and mechanical ventilation.

The researchers noted that “further studies are needed to evaluate the effect of chronic obstructive pulmonary disease, particularly ACO, on COVID-19 mortality.”

Visit Pulmonological advisor conference section for full coverage of AAAAI 2022 Annual Meeting.

Reference

Shin E, Jin J, Park SY, et al. Impact of asthma, COPD and ACO on the prognosis for COVID-19. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting; 25.-28. February 2022; Phoenix, AZ. Abstract 177.

Leave a Reply

Your email address will not be published.